EUVIMEDEUVIMED entdecken
Systematische ÜbersichtOpen Access · CC BY-NC 4.0

Synergistic effects of anticoagulants and platelet aggregation inhibitors with immune checkpoint inhibitors in cancer therapy: a comprehensive review of preclinical and clinical evidence

Julian Kött, Nina Matthes, Alexander T Bauer, Noah Zimmermann, Tim Zell, Daniel J Smit, Stefan W Schneider, Christoffer Gebhardt

Journal for ImmunoTherapy of Cancer · 2026-02 · 14 (2) · e013879

DOI: 10.1136/jitc-2025-013879 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift Journal for ImmunoTherapy of Cancer, online erschienen am 04.02.2026. Verfasst von Julian Kött und 7 weiteren Autor:innen. Beteiligte Einrichtung: Dermatology and Venereology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany j.koett@uke.de. Hauptthemen laut MEDLINE: Anticoagulants, Immune Checkpoint Inhibitors, Neoplasms, Platelet Aggregation Inhibitors. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 54 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The rapidly advancing field of cancer therapy has sparked growing interest in the potential synergy between anticoagulation and immune checkpoint inhibitor (ICI) therapy. Recent research highlights that anticoagulants, traditionally used for thromboprophylaxis and managing thromboembolic events, may also exhibit immunomodulatory properties. These properties can influence the tumor microenvironment by promoting immune cell infiltration, enhancing antitumor immune responses, and potentially reducing metastasis. This emerging evidence underscores the complex interplay between coagulation pathways and immune regulation, paving the way for further exploration of the clinical benefits of combining anticoagulation with ICI therapy.

Methods

A systematic review was conducted to synthesize the current evidence on the interplay between anticoagulation and ICI. Relevant studies examining their mechanisms of action, clinical outcomes, and potential interactions were identified and analyzed. Comprehensive database searches were performed to ensure a thorough and inclusive review of the literature.

Results

Preclinical studies consistently show that combining ICIs with anticoagulants can enhance cancer treatment by inhibiting tumor growth and metastasis. In particular, low molecular weight heparin, oral factor Xa (FXa) inhibitors, and platelet inhibitors have demonstrated synergistic effects with ICI. However, these findings have not been consistently replicated in clinical settings. While two retrospective studies reported no significant impact of anticoagulants on ICI efficacy, one retrospective study found improved outcomes in advanced melanoma patients treated with ICI and FXa inhibitors. Additionally, another retrospective study revealed a significant association between platelet aggregation inhibition and extended progression-free survival.

Conclusions

Our literature review underscores the intricate relationship between anticoagulation and ICIs in cancer therapy. Future studies should prioritize exploring the interactions between ICI, FXa inhibitors, and antiplatelet agents.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AnticoagulantsImmune Checkpoint InhibitorsNeoplasmsPlatelet Aggregation InhibitorsHumansAnimalsDrug Synergism

Stichwörter der Autor:innen

Immune Checkpoint InhibitorsImmunotherapyThrombosis

Substanzen

AnticoagulantsImmune Checkpoint InhibitorsPlatelet Aggregation Inhibitors

Autor:innen und Institutionen

  • Dermatology and Venereology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany j.koett@uke.de.
  • Fleur Hiege Center of Skin Cancer Research, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
  • Dermatology and Venereology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
  • Institute of Tumor Biology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.

Zitieren

APA

Kött, J., Matthes, N., Bauer, A. T., Zimmermann, N., Zell, T., Smit, D. J., Schneider, S. W., & Gebhardt, C. (2026). Synergistic effects of anticoagulants and platelet aggregation inhibitors with immune checkpoint inhibitors in cancer therapy: a comprehensive review of preclinical and clinical evidence. Journal for ImmunoTherapy of Cancer, 14(2), e013879. https://doi.org/10.1136/jitc-2025-013879

Vancouver

Kött J, Matthes N, Bauer AT, Zimmermann N, Zell T, Smit DJ, et al. Synergistic effects of anticoagulants and platelet aggregation inhibitors with immune checkpoint inhibitors in cancer therapy: a comprehensive review of preclinical and clinical evidence. Journal for ImmunoTherapy of Cancer. 2026;14(2):e013879. doi:10.1136/jitc-2025-013879

BibTeX
@article{Ktt2026,
  author = {Kött, Julian and Matthes, Nina and Bauer, Alexander T and Zimmermann, Noah and Zell, Tim and Smit, Daniel J and Schneider, Stefan W and Gebhardt, Christoffer},
  title = {Synergistic effects of anticoagulants and platelet aggregation inhibitors with immune checkpoint inhibitors in cancer therapy: a comprehensive review of preclinical and clinical evidence},
  journal = {Journal for ImmunoTherapy of Cancer},
  year = {2026},
  volume = {14},
  number = {2},
  pages = {e013879},
  doi = {10.1136/jitc-2025-013879}
}
Kostenlos starten →